Knight Therapeutics | GUD - Ordinary Share Capital


Knight Therapeutics reported CAD99.68M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
Acasti Pharma USD 1000 261.04M Dec/2024
Akebia Therapeutics USD 265.42M 199K Dec/2025
Alaunos Therapeutics USD 2.38M 172K Mar/2026
Aurora Cannabis CAD 56.71M 134.13K Dec/2025
Canopy Growth CAD 368.28M 35.9M Dec/2025
Cronos Group USD 376.26M 5.33M Mar/2026
Dianthus Therapeutics USD 43.22M 368.53K Dec/2025
Ionis Pharmaceuticals USD 165.9M 3.93M Mar/2026
IQVIA Holdings USD 166.9M 2.7M Mar/2026
Knight Therapeutics CAD 99.68M 24.66K Sep/2025
Moderna USD 391M 2M Sep/2025
Omeros USD 611K 17K Dec/2023
Organigram Holdings CAD 135.13M 671.75K Dec/2025
Organon & Co USD 260.32M 333K Dec/2025
Revvity USD 111.8M 1.57M Mar/2026
Tectonic Therapeutic USD 18.74M 25.03K Dec/2025
Tilray USD 116.52M 5.01M Sep/2025
Viatris USD 1.16B 5.27M Mar/2026
Xeris Pharmaceuticals USD 166.22M 687.16K Dec/2025